AEON insider transaction filings

AEON Biopharma, Inc. — 23 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-21. Screen AEON transaction legs live →

FiledFormInsiderReported transactionsSource
2026-08-214LYNCH TIMOTHY P — 10% ownerPurchase (P): 1,150,000 @ $0.21EDGAR
2026-06-224Forth Marc — DirectorGrant/award (A): 222,684 @ $0EDGAR
2026-06-224Carter Eric G — DirectorGrant/award (A): 222,684 @ $0EDGAR
2026-06-224FISCHER JOST — DirectorGrant/award (A): 222,684 @ $0EDGAR
2026-06-224Thunen Shelley B — DirectorGrant/award (A): 222,684 @ $0EDGAR
2026-06-224PALMISANO ROBERT J — DirectorGrant/award (A): 222,684 @ $0EDGAR
2026-04-034Bencich John — CHIEF FINANCIAL OFFICERGrant/award (A): 754,717 @ $0EDGAR
2026-03-114Oh Chad — CHIEF MEDICAL OFFICERGrant/award (A): 862,500 @ $0 · Grant/award (A): 1,316,872 @ $0EDGAR
2026-03-054Wilson Alexander Blair — CLO, CSO, and Corp SecretaryGrant/award (A): 862,500 @ $0 · Grant/award (A): 1,316,872 @ $0EDGAR
2026-03-054Sy Jennifer — PRINCIPAL ACCOUNTING OFFICERGrant/award (A): 575,000 @ $0 · Grant/award (A): 925,925 @ $0EDGAR
2026-02-194Bancroft Robert E. — PRESIDENT & CEO, DirectorGrant/award (A): 3,000,000 @ $0EDGAR
2025-05-234Wilson Alexander Blair — Exec VP, CLO & Corp SecretaryGrant/award (A): 1,316,872 (derivative) @ $0EDGAR
2025-05-234Oh Chad — Chief Medical OfficerGrant/award (A): 1,316,872 (derivative) @ $0EDGAR
2025-05-234Sy Jennifer — Chief Accounting OfficerGrant/award (A): 925,925 (derivative) @ $0EDGAR
2025-05-234Forth Marc — DirectorGrant/award (A): 370,370 (derivative) @ $0EDGAR
2025-05-234Carter Eric G — DirectorGrant/award (A): 308,641 (derivative) @ $0EDGAR
2025-05-234FISCHER JOST — DirectorGrant/award (A): 308,641 (derivative) @ $0EDGAR
2025-05-234FISCHER JOST — DirectorPurchase (P): 60,000 @ $0.49EDGAR
2025-05-234Thunen Shelley B — DirectorGrant/award (A): 308,641 (derivative) @ $0EDGAR
2025-05-234PALMISANO ROBERT J — DirectorGrant/award (A): 308,641 (derivative) @ $0EDGAR
2025-05-214FISCHER JOST — DirectorPurchase (P): 50,000 @ $0.50 · Purchase (P): 60,000 @ $0.51EDGAR
2025-05-164Bancroft Robert E. — President & CEO, DirectorGrant/award (A): 177,103 @ $0EDGAR
2025-05-014Bancroft Robert E. — President & CEO, DirectorGrant/award (A): 59,034 (derivative) @ $0EDGAR

Recent 8-K events — AEON Biopharma, Inc.

FiledFormItems reportedSource
2026-08-128-K2.02 — Results of Operations and Financial Condition
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-038-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-238-K8.01 — Other EventsEDGAR
2026-07-158-K1.01 — Entry into a Material Definitive Agreement
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-178-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2026-05-148-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-05-148-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-04-038-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
9.01 — Financial Statements and Exhibits
EDGAR
2026-03-308-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-03-098-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=AEON returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →